EMA Scientific Advice vs. FDA Pre-Submission Meetings — How the Two Systems Differ for CMC Strategy

EMA scientific advice is not a regulatory commitment. The SAWP advice document says so explicitly — and the CHMP reviewer who assesses your MAA Module 3 has not read your SAWP advice document and is not bound by it.

FDA Type B meeting minutes aren’t legally binding either, but FDA reviews them at NDA filing and holds its own examiners to the positions documented there. If EMA’s SAWP advised that an impurity specification is acceptable and the CHMP Rapporteur later disagrees in a Day 70 assessment question, there’s no procedural standing to invoke the SAWP advice as precedent. If FDA’s Type B minutes documented agreement and the NDA reviewer departs from it, there’s real grounds to reference those minutes in response, and FDA’s project management structure escalates that discrepancy internally. These aren’t equivalent systems, and treating them as equivalent has cost CMC programs specification battles they didn’t need to fight.

FDA Type B Pre-NDA Meeting — Meeting Minutes as a De Facto CMC Commitment and the Written-Response-Only Format That Delivers FDA’s Position Without a Live Meeting

FDA’s Guidance for Industry on Formal Meetings establishes three meeting types, with Type B covering major development milestones, including the pre-NDA meeting, scheduled within roughly 60 days of FDA’s acceptance of the meeting request. The process starts with a meeting request containing a concise summary of purpose and a specific list of CMC questions, commonly recommended at up to 25, followed several weeks later by a Meeting Briefing Document capped around 30 pages. FDA reviews that package and issues preliminary responses to the sponsor’s questions, the Pre-Meeting Minutes, before the meeting itself takes place, and for CMC-specific questions those preliminary responses are frequently accepted as FDA’s final position outright, converting what would have been a face-to-face meeting into a written-response-only exchange, a format FDA now uses for a substantial share of Type B CMC meetings. The final meeting minutes, issued within 30 days of the meeting or the WRO response, document FDA’s agreed positions on each submitted question, and those minutes carry real weight at NDA review: the CMC reviewer references them directly, cross-checking the application’s actual approach against what FDA previously agreed to, and a reviewer departure from a documented agreement requires escalation to the Division Director before a contradicting deficiency can be issued. The highest-value CMC questions to bring into this process are the ones with the most submission risk attached: proposed specification limits and their justification for a novel drug substance, the in-process control strategy for a complex manufacturing process, the stability protocol and proposed extrapolation approach, and manufacturing site information tied to inspection history.

EMA SAWP Scientific Advice — Day 70 Assessment, Non-Binding Opinion, and Why the CHMP Rapporteur at MAA Review Is Not Your SAWP Rapporteur

EMA’s Procedure for Scientific Advice and Protocol Assistance establishes a structurally similar-looking process that functions very differently in practice. A scientific advice request goes in through EMA’s submission portal accompanied by a Scientific Background document and a List of Questions split across clinical, non-clinical, and quality sub-lists. SAWP assigns a Rapporteur and Co-Rapporteur drawn from CHMP member state assessors, the Rapporteur delivers a Day 70 Assessment Report responding to each question, the applicant submits a response document, and SAWP issues its final Advice Document around Day 100. The critical difference from the FDA process sits in what that Advice Document actually says about itself: EMA’s procedural guidance states explicitly that scientific advice and protocol assistance are not legally binding on the applicant, on EMA, or on its committees, and that the advice does not prejudge the outcome of the actual CHMP assessment. In practice, SAWP advisors are often drawn from the same pool of national assessors who later serve as CHMP Rapporteurs on MAAs, but there’s no guarantee the specific Rapporteur assigned to a given MAA is the same person who provided the SAWP advice, which means a specification or manufacturing approach the SAWP validated can be questioned fresh by a different CHMP Rapporteur at Day 70 of the actual MAA review, with the earlier SAWP advice carrying no procedural standing as a binding precedent in that assessment.

When FDA and EMA Disagree on CMC — Specification Harmonization Decision, Global Specification Selection, and the Post-Approval Change Cost of Filing Different Specs in Two Markets

The most consequential decision point in a parallel FDA/EMA CMC program is what happens when the two systems’ outputs genuinely disagree. ICH Q3B(R2) establishes the impurity qualification threshold framework both agencies apply, but a specific case illustrates how the same underlying framework can produce different agency positions: FDA’s Type B meeting minutes might document agreement that a 0.10% reporting threshold is sufficient for an impurity given the intended patient population and route of administration, while EMA’s SAWP recommends the more conservative 0.05% qualification threshold appropriate to a parenteral product with long-term dosing. Facing that disagreement, the more defensible resolution is adopting the more stringent EMA-recommended limit as the single global specification, filed identically in both the FDA NDA and the EMA MAA, rather than filing two different specifications across markets. The reasoning isn’t regulatory formality, it’s operational: a single specification exceedance under a harmonized global limit triggers a consistent quality response across markets, while two different specifications create a scenario where an exceedance against the tighter EU limit doesn’t trigger the same GMP response in the US market, a compliance complexity most quality systems aren’t built to manage cleanly. The real cost of the conservative path shows up earlier, before filing, if the tighter specification isn’t yet achievable with the current manufacturing process, in which case the process improvement work needed to hit it has to be completed before NDA submission, adding real timeline and cost rather than being deferred to a post-approval harmonization exercise.

The XGene FDA/EMA Parallel Pre-Submission CMC Strategy Architecture — Type B Meeting Preparation, SAWP Request Design, Position Harmonization, ROI Analysis, and Parallel Program Coordination

The XGene FDA/EMA Parallel Pre-Submission CMC Strategy Architecture is a structured framework for pre-submission CMC strategy in parallel FDA and EMA programs built around the recognition that the two systems’ outputs carry fundamentally different binding authority.

1. FDA Type B Pre-NDA Meeting Preparation — Prioritize the CMC questions with the highest submission risk, specification justification, in-process controls, stability protocol, and manufacturing site status, and design the Briefing Document to maximize the odds of an actionable WRO response. 2. EMA SAWP Scientific Advice Request Design — Submit the quality List of Questions with full awareness that the Day 100 Advice Document is a scientific opinion, not a CHMP commitment, and plan accordingly rather than treating it as a filing guarantee. 3. FDA/EMA CMC Position Harmonization Protocol — Where the two agencies’ pre-submission positions diverge, default to the more conservative position as the single global specification unless a documented scientific rationale supports maintaining separate regional limits. 4. Pre-Submission Meeting ROI Analysis — Weigh the Type B meeting and SAWP request investment against the Phase 3 CMC development cost each is meant to de-risk, recognizing the two carry different cost-to-certainty ratios. 5. Parallel Program Coordination Sequencing — Sequence FDA meeting minutes as the anchor global CMC design decision, using SAWP advice as a validation checkpoint rather than a second independent commitment.

The output is the pre-submission CMC strategy that extracts genuine value from both systems without mistaking EMA’s scientific opinion for the regulatory commitment only FDA’s Type B minutes actually represent.

FDA’s Guidance for Industry: Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products (2009) establishes the Type B meeting request format, scheduling target, and final meeting minutes process this article’s analysis is built around. The EMA Procedure for Scientific Advice and Protocol Assistance (EMA/CHMP/726620/2016) establishes the SAWP request and assessment timeline and explicitly confirms the non-binding nature of SAWP advice, while ICH M4Q(R1) establishes the CTD Module 3 framework guiding which CMC topics are most productively raised in either process. ICH Q3B(R2) establishes the impurity qualification threshold standard whose regional application can create the FDA/EMA specification disagreement this article addresses.

For your parallel FDA/EMA development program, have you submitted a Type B pre-NDA meeting request with specific CMC questions on specification limits, stability protocol, and manufacturing site status, and is your EMA SAWP interaction planned with the explicit understanding that the SAWP advice is non-binding and may not match FDA’s Type B meeting agreement, requiring a global specification harmonization decision before Phase 3 completes?